In:
Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 146, No. Suppl_1 ( 2022-11-08)
Abstract:
Introduction: Risk stratification is an integral component of the management strategy in patients with non-ST-elevation myocardial infarction (NSTEMI). Multiple risk scores have been proposed however, these have not been validated in developing countries such as India. Hypothesis: This study aims to determine the various prognostic factors in patients with NSTEMI as well as to compare and validate the performance of different risk stratification scores in these subjects. Methods: This was a single center prospective observational study wherein diagnosed with NSTEMI were enrolled. A detailed clinical history including symptomatology, presence of risk factors and family history were recorded. In all enrolled patients based on the prospectively collected data, five risk scores i.e. TIMI, GRACE version 2.0, PURSUIT, HEART and CAMI-NSTEMI were computed. Outcome data in terms of both in-patient as well as at 14 days, six months and one year major adverse cardiovascular events (MACE) were obtained. Results: A total of 1102 patients were enrolled with a mean age of 59.6 ± 11.2 years. MACE occurred in 140/1102 subjects (12.7%) with mortality in 89 (8.1%) patients. Patients with MACE were elderly, had higher frequency of smoking, hypertension, diabetes and stroke. Multivariate logistic regression analysis revealed that angina in last 48 hours, diabetes, smoking, cardiac arrest on presentation and fragmented QRS on ECG were independent predictors of MACE. All risk scores were able to predict MACE events equally well however, for in-hospital MACE, TIMI risk score had the highest predictive ability. However, for 14-day, 6 month and one year MACE, GRACE scores had highest predictive ability. Conclusions: Our study showed that all risk scores had a good predictive ability for both short term as well as intermediate-term MACE events.
Type of Medium:
Online Resource
ISSN:
0009-7322
,
1524-4539
DOI:
10.1161/circ.146.suppl_1.14424
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
1466401-X
Permalink